Class: Antipsychotic agent, Benzisoxazole derivative
- Tablets, ER, oral 1.5 mg
- Tablets, ER, oral 3 mg
- Tablets, ER, oral 6 mg
- Tablets, ER, oral 9 mg
- Injection, suspension, ER 39 mg per 0.25 mL
- Injection, suspension, ER 78 mg per 0.5 mL
- Injection, suspension, ER 117 mg per 0.75 mL
- Injection, suspension, ER 156 mg/mL
- Injection, suspension, ER 234 mg per 1.5 mL
Possibly due to dopamine and serotonin receptor blockade in the CNS. Also an antagonist at alpha-1 and alpha-2 adrenergic receptors and H 1 histaminic receptors. Paliperidone is the active metabolite of risperidone.
Dose-related pharmacokinetics. Oral bioavailability is approximately 28%. C max occurs approximately 24 h after oral dosing. Steady-state concentrations are reached within 4 to 5 days of oral dosing. Mean steady-state peak-to-trough ratio ranges from 1.2 to 3.1 (oral). Following a single IM dose, T max was 13 days and mean steady-state peak-to-trough ratio was 1.8 (gluteal administration) and 2.2 (deltoid administration). After IM administration, the release of the drug starts as early as day 1 and lasts for as long as 126 days.
Vd is 487 L (oral) and 391 L (IM). Plasma protein binding is 74%.
Four metabolite pathways: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission. Limited degree of metabolism by CYP2D6 and CYP3A4.
Elimination half-life is approximately 23 h (oral). Elimination of the injection is approximately 80% in urine and 11% in feces; 32% of the oral dose is recovered as metabolites. The mean apparent half-life following a single IM dose (39 to 243 mg) ranged from 25 to 49 days.
Special PopulationsRenal Function Impairment
Reduce oral dose in patients with moderate or severe impairment and reduce IM injection dose in patients with mild impairment. The IM injection is not recommended in patients with moderate or severe renal impairment.Hepatic Function Impairment
No adjustments needed in patients with mild or moderate impairment. Effect of severe impairment has not been determined.Elderly
Dosage adjustment is not recommended based on age alone; however, dosage adjustments may be needed based on renal function.Gender
Slower IM absorption observed in women; dosage adjustment based on gender is not recommended.Race
Dosage adjustment based on race is not recommended.
Indications and Usage
Acute and maintenance treatment of schizophrenia; treatment of schizoaffective disorder as monotherapy or as an adjunct to mood stabilizers and/or antidepressants (oral only).
Hypersensitivity to risperidone, paliperidone, or any component of the product.
Dosage and AdministrationSchizoaffective Disorder
PO 6 mg once daily (range, 3 to 12 mg/day). Dosage increases should only occur at intervals of no more than 4 days in increments of 3 mg/day (max, 12 mg/day).Schizophrenia
6 mg once daily (range, 3 to 12 mg/day). Dosage increases should be made at increments of 3 mg/day at intervals of at least 5 days (max, 12 mg/day).IM
234 mg on treatment day 1 and 156 mg 1 wk later, both administered in the deltoid muscle. Monthly maintenance dose is 117 mg administered in deltoid or gluteal muscle; recommended dose range is 39 to 234 mg based on individual tolerability and efficacy. Adjust maintenance dose monthly.Adolescents (12 to 17 y of age)
PO 3 mg once daily. Dosage increases should be made at increments of 3 mg/day at intervals of at least 5 days (max, 6 mg/day for patients weighing less than 51 kg; 12 mg/day for patients weighing 51 kg or more).Missed Doses Adults
IM To avoid a missed dose, give the second dose 2 days before or after the 1-wk time point. Similarly, the third and subsequent injections after the initiation regimen are recommended to be given monthly. To avoid a missed monthly dose, patients may be given the injection up to 7 days before or after the monthly time point. If more than 6 wk have elapsed since the last dose, resume the same dose the patient was stabilized on (unless the patient was stabilized on 234 mg, then the first 2 injections should each be 156 mg) in the following manner: a deltoid injection as soon as possible, followed by another deltoid injection (same dose) 1 wk later, and resumption of either deltoid or gluteal dosing at monthly intervals. If more than 6 mo have elapsed since the last injection, dosing should be restarted.Switching from Oral to IM
3 mg/day orally converts to 39 to 78 mg/mo IM; 6 mg/day orally converts to 117 mg/mo IM; 12 mg/day orally converts to 234 mg/mo IM.Switching from Long-Acting Injectable Antipsychotics
IM Initiate paliperidone in place of the next scheduled injection. Continue at monthly intervals. The 1-wk initiation regimen is not required.Renal Function Impairment PO
For mild impairment (CrCl 50 to less than 80 mL/min), recommended initial dosage is 3 mg/day, not to exceed 6 mg once daily. For moderate to severe impairment (CrCl 10 to less than 50 mL/min), recommended initial dosage is 1.5 mg/day, not to exceed 3 mg once daily.IM
For mild impairment, initiate with 156 mg on treatment day 1 and 117 mg 1 wk later, both administered in deltoid muscle. Continue with 78 mg monthly in the deltoid or gluteal muscle. The IM injection is not recommended in patients with moderate to severe renal impairment.
- May be taken with or without food.
- Tablets must be swallowed whole and not divided, chewed, or crushed.
- Initial dose titration is not required.
- For IM use only; inject slowly, deep into muscle.
- Injection is for single use only.
- Do not administer intravascularly or subcutaneously.
Store at 59° to 86°F. Protect from moisture.
Drug InteractionsAlcohol, CNS-acting drugs
Use CNS-acting drugs with caution. Avoid alcohol.Antihypertensive agents
Effects may be enhanced by paliperidone. Alpha-blocking activity of paliperidone may induce orthostatic hypotension and syncope. Monitor BP and orthostatic vital signs.Carbamazepine
Paliperidone plasma concentrations and AUC may be reduced, decreasing the efficacy. Evaluate the paliperidone dose when carbamazepine is started or stopped. Adjust the paliperidone dose as needed.Charcoal
Paliperidone absorption may be decreased, reducing the efficacy.Divalproex sodium, valproate sodium, valproic acid
Paliperidone C max and AUC may be elevated, increasing the pharmacologic effects and risk of adverse reactions. Evaluate the clinical response of the patient when valproic acid is started or stopped. Adjust the paliperidone dose as needed.Drugs that cause orthostatic hypotension
Possible additive effect with paliperidone.Drugs that prolong the QTc interval (eg, antibiotics [gatifloxacin, moxifloxacin], antipsychotic agents [eg, chlorpromazine, thioridazine], arsenic trioxide, chloroquine, cisapride, class IA antiarrhythmic agents [eg, procainamide, quinidine], class III antiarrhythmic agents [eg, amiodarone, dofetilide, sotalol], dronedarone, halofantrine, haloperidol, macrolide antibiotics [eg, erythromycin], maprotiline, methadone, romidepsin, tetrabenazine, toremifene, tyrosine kinase receptor antagonists [eg, lapatinib], vandetanib)
Risk of life-threatening arrhythmias, including torsades de pointes, may be increased. Avoid coadministration of paliperidone with these agents.Food
Administration of paliperidone with a standard high-fat/high-caloric meal may increase paliperidone mean C max and AUC values compared with administration under fasting conditions. However, paliperidone may be taken without regard to food.Levodopa and other dopamine agonists
Effects may be antagonized by paliperidone.Paroxetine
Paliperidone exposure may be increased. Evaluate the clinical response of the patient when paroxetine is started or stopped. Adjust the paliperidone dose as needed.Sympathomimetics (eg, dopamine, epinephrine)
For treatment of paliperidone-induced hypotension, do not use dopamine or other sympathomimetics with beta-agonist activity because beta stimulation may worsen the hypotension caused by paliperidone-induced alpha blockade.
Tachycardia (14%); orthostatic hypotension (4%); bundle branch block (3%); first-degree AV block, sinus arrhythmia (2%); bradycardia, hypertension, hypotension, palpitations, syncope (less than 2%).Injection
Hypertension (2%); bradycardia; bundle branch block; cerebrovascular accident; first-degree AV block; palpitations; postural orthostatic tachycardia syndrome; QT prolonged; syncope; tachycardia.
Somnolence (26%); extrapyramidal disorder (20%); akathisia, hyperkinesia (17%); parkinsonism (15%); dystonia, headache (14%); tremor (12%); anxiety, dyskinesia (9%); dizziness (6%); asthenia, dysarthria, fatigue (4%); lethargy, sleep disorder (3%); agitation, insomnia, nightmare, opisthotonus (less than 2%); tardive dyskinesia (postmarketing).Injection
Headache, insomnia (15%); parkinsonism (12%); agitation (10%); anxiety (8%); somnolence/sedation (7%); akathisia, dizziness, dyskinesia (6%); extrapyramidal disorder (5%); hyperkinesia (4%); tremor (3%); asthenia, dystonia, fatigue, nightmare, suicidal ideation (2%); bradykinesia; convulsions; dizziness postural; drooling; dysarthria; dystonia; hypertonia; lethargy; NMS; oromandibular dystonia; psychomotor hyperactivity; restlessness; tardive dyskinesia; vertigo.
Pruritus, rash (less than 2%).Injection
Injection-site reactions (10%); skin laceration (2%); drug eruption; pruritus; rash; urticaria.
Vision blurred (3%); eye movement disorder.Injection
Eye movement disorder, eye rolling, oculogyric crisis, vision blurred.
Vomiting (11%); nausea (8%); dyspepsia, salivary hypersecretion (6%); constipation (5%); abdominal discomfort/upper abdominal pain, dry mouth, increased appetite, swollen tongue, tongue paralysis (3%); decreased appetite, stomach discomfort (2%); flatulence (less than 2%).Injection
Constipation, vomiting (5%); abdominal discomfort/abdominal pain upper, nausea (4%); diarrhea, dry mouth, toothache (3%); increased or decreased appetite; salivary hypersecretion; swollen tongue (postmarketing).
Amenorrhea (6%); galactorrhea (4%); gynecomastic (3%); breast discomfort, menstruation irregular, retrograde ejaculation, UTI (less than 2%); priapism, urinary incontinence, urinary retention (postmarketing).Injection
UTI (2%); amenorrhea; breast discharge; erectile dysfunction; galactorrhea; gynecomastia; menstrual disorder; menstruation delayed; menstruation irregular; sexual dysfunction; priapism, urinary incontinence, urinary retention (postmarketing).
ALT increased, AST increased (less than 2%).Injection
ALT increased (2%); abnormal ECG, increased blood glucose, increased cholesterol, increased triglycerides.
Weight gain (7%); edema (less than 2%).Injection
Weight gain (4%); hyperglycemia, hyperinsulinemia.
Myalgia (4%); back pain (3%) pain in extremity (less than 2%).Injection
Back pain, pain in extremity (3%); musculoskeletal stiffness, myalgia (2%); joint stiffness, muscle rigidity, muscle spasms, muscle tightness, muscle twitching, nuchal rigidity.
Nasopharyngitis (5%); cough, rhinitis (3%); pharyngolaryngeal pain, upper respiratory tract infection (2%); nasal congestion (less than 2%).Injection
Nasopharyngitis, upper respiratory tract infection (4%); cough (3%).
Anaphylactic reaction (less than 2%); angioedema (postmarketing).Injection
Hyperprolactinemia; angioedema (postmarketing).
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared with those taking placebo. Although the causes of death were varied, most of the deaths appeared to be either CV (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Paliperidone is not approved for the treatment of dementia-related psychosis.
Consider monitoring renal function in elderly patients. Monitor CBC during the first few months of therapy in patients with a history of clinically significant low WBC or drug-induced leukopenia/neutropenia. Monitor diabetic patients regularly for worsening of glucose control and for symptoms of hyperglycemia, including polydipsia, polyuria, polyphagia, and weakness. Ensure that patients with risk factors for diabetes mellitus (eg, obesity, family history of diabetes) who are starting atypical antipsychotic therapy undergo fasting blood glucose testing at the beginning of treatment and periodically thereafter. Monitor orthostatic vital signs in patients who are vulnerable to hypotension. Periodically reassess patients to determine the need for continued treatment. Suicide attempt is inherent in psychotic illnesses; closely monitor high-risk patients during drug therapy. If a patient requires paliperidone treatment after recovery from NMS, carefully monitor the patient because recurrences of NMS have been reported.
Category C . Neonates exposed to antipsychotics during the third trimester of pregnancy are at risk of extrapyramidal and/or withdrawal symptoms.
Excreted in breast milk. Breast-feeding women should not breast-feed when receiving paliperidone injection.
Safety and efficacy in the treatment of schizophrenia not established in patients younger than 12 y. Safety and efficacy not established in the treatment of schizoaffective disorder.Injection
Safety and efficacy not established.
Adjust dose according to renal function.
Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been observed.
Individualize the oral dose according the patient's renal function status. Dosage adjustment is recommended for the injection doseform when used in patients with mild renal impairment; paliperidone injection is not recommended for patients with moderate or severe renal impairment.
Special Risk Patients
Patients with Parkinson disease or dementia with Lewy bodies may have increased sensitivity to paliperidone, which may manifest as confusion, extrapyramidal symptoms, NMS, obtundation, or postural instability with frequent falls.
Because paliperidone may have an antiemetic effect, signs and symptoms of overdosage with certain drugs or conditions (eg, brain tumor, intestinal obstruction) may be masked.
Body temperature regulation
Antipsychotics disrupt the ability to reduce core body temperature. Use with caution in patients who will experience conditions that may contribute to an elevation in core body temperature (eg, concomitant anticholinergic therapy, dehydration, exposure to extreme heat, strenuous exercise).
Cerebrovascular events (eg, stroke, transient ischemic attack), including fatalities, have been seen in elderly patients with dementia-related psychoses. Use with caution.
Cognitive and motor performance
Judgment, thinking, or motor skills may be impaired.
Because QTc prolongation may occur, avoid use in patients receiving other drugs that prolong the QTc interval and in patients with congenital long QT syndrome or history of cardiac arrhythmias. Use with caution in patients with known CV disease (eg, heart failure, history of MI).
Antipsychotics have been associated with esophageal dysmotility and aspiration. Use with caution in patients at risk of aspiration pneumonia.
Because tablet does not change shape in the GI tract, do not administer paliperidone to patients with preexisting severe GI narrowing (eg, cystic fibrosis).
Leukopenia, neutropenia, and agranulocytosis have been reported.
Hyperglycemia and diabetes mellitus
Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported.
Prolactin levels may be elevated.
Has occurred and is potentially fatal. Signs and symptoms include altered mental status, diaphoresis, hyperpyrexia, irregular BP, irregular pulse, muscle rigidity, and tachycardia.
Orthostatic hypotension associated with bradycardia, dizziness, syncope, and tachycardia may occur. Use with caution in patients with cerebrovascular disease, CV disease (eg, heart failure), or conditions that predispose the patient to hypotension (eg, dehydration, hypovolemia).
May occur; severe priapism may require surgical intervention.
May occur; use with caution in patients with a history of seizures or other conditions that potentially lower the seizure threshold.
Possible suicide attempts are inherent in psychotic illnesses. Supervise high-risk patients. Prescribe lowest quantity consistent with good patient management in order to reduce risk of overdose.
Syndrome of potentially irreversible, involuntary dyskinetic movements may develop. Prevalence is higher in elderly patients, especially women. Use lowest effective dose for shortest period of time needed.
Drowsiness, extrapyramidal symptoms, hypotension, QT prolongation, sedation, tachycardia, torsades de pointes, unsteady gait, ventricular fibrillation.
- Advise patient that drug may cause drowsiness or impaired judgment or thinking skills, and to use caution while driving, riding a bike, or performing other tasks requiring mental alertness until tolerance is determined.
- Advise patient to get up slowly from a lying or sitting position and to avoid sudden position changes to prevent postural hypotension.
- Advise patient to avoid alcohol while taking paliperidone.
- Advise patient to avoid strenuous activity during periods of high temperature or humidity and to avoid overheating and dehydration.
- Advise patient to swallow tablet whole, and not to divide, chew, or crush.
- Advise patients that the tablet shell may be eliminated through the stool.
- Advise patients not to breast-feed during therapy.
- Advise patients to notify their health care provider if they become pregnant or intend to become pregnant during treatment.
Copyright © 2009 Wolters Kluwer Health.
More Paliperidone resources
- Paliperidone Monograph (AHFS DI)
- paliperidone MedFacts Consumer Leaflet (Wolters Kluwer)
- paliperidone Advanced Consumer (Micromedex) - Includes Dosage Information
- Invega Prescribing Information (FDA)
- Invega Consumer Overview
- Invega extended-release tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- Invega Sustenna Prescribing Information (FDA)
- Invega Sustenna Advanced Consumer (Micromedex) - Includes Dosage Information